Aldeyra Therapeutics Abstracts Accepted for Presentation at the 2015 Annual Meeting of the Association for Research in Vision and Ophthalmology

LEXINGTON, Mass., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on its lead product candidate, NS2, has been accepted for two poster presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting, being held May 3-7, 2015 in Denver, Colorado.

Aldeyra will present the objectives, methods and results of studies evaluating a small molecule aldehyde trapping agent, NS2, an investigational drug in development for acute noninfectious anterior uveitis.

The abstract presentation titles are as follows:

  • The Aldehyde Trap NS2 Mitigates Dense Haze in a Rabbit Model of Photorefractive Keratectomy
  • The Aldehyde Trap NS2 Reduces Ocular Inflammation in an Endotoxin-Induced Model in Rats

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, commented, "We are excited to present two posters on our lead product candidate, NS2, at ARVO this year. These preclinical studies demonstrate the effectiveness of NS2 in reducing ocular inflammation as well as mitigating haze, a form of scarring or fibrosis, following photorefractive keratectomy (PRK), a type of laser eye surgery. The ocular inflammation data support NS2 as an effective agent when compared to corticosteroids, which are toxic when used chronically in the eye. With these data and our recent IND submission for noninfectious anterior uveitis, we are well-positioned to evaluate our aldehyde trap in upcoming clinical trials as a steroid adjunct or replacement."

Noninfectious anterior uveitis is a rare inflammatory ocular disease that causes pain, photophobia and loss of vision, and affects an estimated 25,000 individuals in the U.S. NS2 is an aldehyde-binding small molecule based on an innovative platform technology focused on trapping free aldehydes, which are toxic and pro-inflammatory mediators of numerous diseases. By decreasing aldehyde load, NS2 may mitigate pathologic inflammation. As a product candidate, NS2 is currently being evaluated to address two underserved rare diseases, noninfectious anterior uveitis and Sjögren-Larsson Syndrome.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to initiate Phase II clinical studies of NS2 in noninfectious anterior uveitis and Sjögren-Larsson Syndrome in 2015. NS2 has not been approved for sale in the U.S. or elsewhere.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra's plans for its product candidates. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; Aldeyra's ability to attract or retain key personnel; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Aldeyra's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the Securities and Exchange Commission (SEC) and available on the SEC's website at

In addition to the risks described above and in Aldeyra's other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

CONTACT: Corporate Contact: Stephen Tulipano Aldeyra Therapeutics, Inc. Tel: +1 781-761-4904 Ext. 205 Investor Contact: David Burke The Ruth Group Tel: +1 646-536-7009 dburke@theruthgroup.comSource:Aldeyra Therapeutics